Louisiana State Staff Retirement Machine raised its stake in stocks of Arrowhead Prescribed drugs, Inc. (NASDAQ:ARWR – Get Score) by means of 3.0{aaa84efcd05d20dc7d0e48929bb8fd8c8895020217096fb46d833d790411cbb9} within the 1st quarter, Holdings Channel stories. The company owned 27,600 stocks of the biotechnology corporate’s inventory after buying an extra 800 stocks all through the quarter. Louisiana State Staff Retirement Machine’s holdings in Arrowhead Prescribed drugs had been value $1,263,000 on the finish of the newest quarter.
Plenty of different massive traders additionally just lately made adjustments to their positions in ARWR. Millennium Control LLC raised its place in Arrowhead Prescribed drugs by means of 242.2{aaa84efcd05d20dc7d0e48929bb8fd8c8895020217096fb46d833d790411cbb9} all through the third quarter. Millennium Control LLC now owns 48,019 stocks of the biotechnology corporate’s inventory value $2,998,000 after buying an extra 33,988 stocks all through the final quarter. UBS Asset Control Americas Inc. raised its place in Arrowhead Prescribed drugs by means of 12.4{aaa84efcd05d20dc7d0e48929bb8fd8c8895020217096fb46d833d790411cbb9} all through the third quarter. UBS Asset Control Americas Inc. now owns 98,492 stocks of the biotechnology corporate’s inventory value $6,149,000 after buying an extra 10,831 stocks all through the final quarter. Lindbrook Capital LLC raised its place in Arrowhead Prescribed drugs by means of 10,300.0{aaa84efcd05d20dc7d0e48929bb8fd8c8895020217096fb46d833d790411cbb9} all through the 4th quarter. Lindbrook Capital LLC now owns 1,144 stocks of the biotechnology corporate’s inventory value $76,000 after buying an extra 1,133 stocks all through the final quarter. Atlantic Non-public Wealth LLC purchased a brand new place in Arrowhead Prescribed drugs all through the 4th quarter value $438,000. In spite of everything, MBE Wealth Control LLC raised its place in Arrowhead Prescribed drugs by means of 3.7{aaa84efcd05d20dc7d0e48929bb8fd8c8895020217096fb46d833d790411cbb9} all through the 4th quarter. MBE Wealth Control LLC now owns 6,525 stocks of the biotechnology corporate’s inventory value $433,000 after buying an extra 230 stocks all through the final quarter. 64.62{aaa84efcd05d20dc7d0e48929bb8fd8c8895020217096fb46d833d790411cbb9} of the inventory is owned by means of institutional traders and hedge budget.
Stocks of ARWR opened at $41.73 on Friday. The inventory has a 50-day shifting reasonable of $34.33 and a 200-day shifting reasonable of $44.56. Arrowhead Prescribed drugs, Inc. has a twelve months low of $26.81 and a twelve months top of $84.83.
Arrowhead Prescribed drugs (NASDAQ:ARWR – Get Score) final issued its income effects on Tuesday, Might tenth. The biotechnology corporate reported $0.41 EPS for the quarter, beating the consensus estimate of $0.39 by means of $0.02. The corporate had earnings of $151.80 million all through the quarter, in comparison to the consensus estimate of $122.15 million. Arrowhead Prescribed drugs had a detrimental go back on fairness of 26.77{aaa84efcd05d20dc7d0e48929bb8fd8c8895020217096fb46d833d790411cbb9} and a detrimental web margin of 42.44{aaa84efcd05d20dc7d0e48929bb8fd8c8895020217096fb46d833d790411cbb9}. The company’s earnings for the quarter used to be up 362.8{aaa84efcd05d20dc7d0e48929bb8fd8c8895020217096fb46d833d790411cbb9} in comparison to the similar quarter final yr. Right through the similar length final yr, the industry posted ($0.26) EPS. On reasonable, sell-side analysts forecast that Arrowhead Prescribed drugs, Inc. will publish -1.03 income in step with proportion for the present fiscal yr.
A number of analysis analysts just lately issued stories at the corporate. StockNews.com raised Arrowhead Prescribed drugs from a “promote” ranking to a “dangle” ranking in a analysis record on Monday, Might twenty third. HC Wainwright lifted their value purpose on Arrowhead Prescribed drugs from $100.00 to $110.00 and gave the inventory a “purchase” ranking in a analysis record on Friday, June third. Robert W. Baird raised Arrowhead Prescribed drugs from a “impartial” ranking to an “outperform” ranking and decreased their value purpose for the inventory from $71.00 to $60.00 in a analysis record on Wednesday, Might eleventh. Cantor Fitzgerald reissued an “obese” ranking on stocks of Arrowhead Prescribed drugs in a analysis record on Friday, April 1st. In spite of everything, The Goldman Sachs Crew decreased their value purpose on Arrowhead Prescribed drugs from $90.00 to $66.00 and set a “purchase” ranking for the corporate in a analysis record on Tuesday, Might twenty fourth. Two equities analysis analysts have rated the inventory with a dangle ranking and 5 have assigned a purchase ranking to the corporate. In step with MarketBeat, the inventory lately has a mean ranking of “Average Purchase” and a mean value goal of $73.00.
About Arrowhead Prescribed drugs (Get Score)
Arrowhead Prescribed drugs, Inc develops drugs for the remedy of intractable illnesses in america. The corporate’s merchandise in pipeline contains ARO-AAT, a RNA interference (RNAi) healing candidate this is in Segment II medical trial for the remedy of liver illnesses related to alpha-1 antitrypsin deficiency; ARO-APOC3, which is in segment 2b and one segment 3 medical trial to regard hypertriglyceridemia; ARO-ANG3 this is in Segment 2b medical trial to cut back manufacturing of angiopoietin-like protein 3; ARO-HSD, which is in Segment 1/2a medical trial to regard liver illnesses; ARO-ENaC, which is in a Segment 1/2a medical trial to cut back manufacturing of the epithelial sodium channel alpha subunit within the airlines of the lung; ARO-C3 for the remedy of complement-mediated illness this is in Segment 1/2a medical trial; ARO-Lung2 for the remedy of continual obstructive pulmonary dysfunction; ARO-DUX4 for the remedy of facioscapulohumeral muscular dystrophy; ARO-XDH to regard out of control gout; ARO-COV for the remedy of COVID-19 and different pulmonary-borne pathogens; and ARO-HIF2, which is in segment 1b medical trial to regard transparent mobile renal mobile carcinoma.
Learn Extra
Wish to see what different hedge budget are preserving ARWR? Consult with HoldingsChannel.com to get the newest 13F filings and insider trades for Arrowhead Prescribed drugs, Inc. (NASDAQ:ARWR – Get Score).
Obtain Information & Rankings for Arrowhead Prescribed drugs Day-to-day – Input your e-mail cope with under to obtain a concise day by day abstract of the newest information and analysts’ scores for Arrowhead Prescribed drugs and comparable corporations with MarketBeat.com’s FREE day by day e-mail e-newsletter.
